Why the study?
Despite improvements in the prognosis of acute myocardial infarction with new biomarkers, medication, and PCI, challenges remain in its diagnosis and management.
Answers are grounded in this paper and cite their sources.
This review highlights emerging diagnostic and therapeutic strategies for acute myocardial infarction aimed at reducing infarct size and preventing adverse ventricular remodeling.
With the discovery of new biomarkers for the early detection of acute myocardial infarction (AMI), advancements in valid medication, and percutaneous coronary intervention (PCI), the overall prognosis of AMI has improved remarkably. Nevertheless, challenges remain which require more difficult work to overcome. Novel diagnostic and therapeutic techniques include new AMI biomarkers, hypothermia therapy, supersaturated oxygen (SSO 2 ) therapy, targeted anti-inflammatory therapy, targeted angiogenesis therapy, and stem cell therapy. With these novel methods, we believe that the infarction size after AMI will decrease, and myocardial injury-associated ventricular remodeling may be avoided. This review focuses on novel advances in the diagnosis and management of AMI.
No takes yet. Share an insight, caveat, or question.
Hsieh et al. (2023) conducted a review in Acute myocardial infarction. Novel diagnostic and therapeutic techniques was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: